Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of [[dopamine receptor|dopamine]], [[Alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]], [[H1 receptor|H<sub>1</sub>]], and [[muscarinic acetylcholine receptor|mACh receptor]] [[receptor antagonist|antagonism]],<ref name="pmid12527336">{{cite journal | vauthors = Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M | title = Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 65 | issue = 3 | pages = 435–40 |date=February 2003 | pmid = 12527336 | doi = 10.1016/S0006-2952(02)01515-0| url = http://linkinghub.elsevier.com/retrieve/pii/S0006295202015150}}</ref> it additionally produces potent blockade of several [[serotonin receptor]]s, including [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub>]].<ref name="pmid12527336"/><ref name="pmid10672635">{{cite journal | vauthors = Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP | title = 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity | journal = Psychopharmacology | volume = 147 | issue = 4 | pages = 412–7 |date=January 2000 | pmid = 10672635 | doi = 10.1007/s002130050010| url = http://link.springer.de/link/service/journals/00213/bibs/0147004/01470412.htm}}</ref><ref name="pmid12421652">{{cite journal | vauthors = Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP | title = 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle | journal = European Journal of Pharmacology | volume = 454 | issue = 2-3 | pages = 235–9 |date=November 2002 | pmid = 12421652 | doi = 10.1016/S0014-2999(02)02489-5| url = http://linkinghub.elsevier.com/retrieve/pii/S0014299902024895}}</ref><ref name="pmid17936750">{{cite journal | vauthors = Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A | title = Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes | journal = European Journal of Pharmacology | volume = 578 | issue = 2-3 | pages = 142–7 |date=January 2008 | pmid = 17936750 | doi = 10.1016/j.ejphar.2007.09.025 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(07)01053-9}}</ref> These actions have been implicated in cyamemazine's anxiolytic effects (5-HT<sub>2C</sub>) and lack of [[extrapyramidal symptom|extrapyramidal]] [[side effect]]s (5-HT<sub>2A</sub>),<ref name="pmid12527336"/><ref name="pmid10672635"/> and despite being classified as a [[typical antipsychotic]], it actually behaves like an [[atypical antipsychotic]].<ref name="pmid12595954">{{cite journal | vauthors = Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M | title = Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 367 | issue = 2 | pages = 134–9 |date=February 2003 | pmid = 12595954 | doi = 10.1007/s00210-002-0665-4 }}</ref>
